4 noiembrie, 2015, Osaka, Japonia –– Santen Pharmaceutical Co., Ltd. (Santen) a anunţat astăzi că National Institute for Health and Care Excellence (NICE) şi-a dat acordul ’’Final Appraisal Determination (FAD)’’ în recomandarea de utilizare a produsului Santen IKERVIS® (ciclosporin1 mg/ml picaturi oftalmice, emulsie în fiole uni-doză) în Anglia pentru tratamentul keratitelor severe la pacienţii adulţi cu sindrom de ochi uscat, a căror stare nu s-a îmbunậtăţit în ciuda tratamentului cu lacrimi artificiale.1 IKERVIS® este primul si singurul preparat topic autorizat pentru tratamentul keratitelor severe la pacienţii cu sindrom de ochi uscat în Marea Britanie.2 IKERVIS® conţine o nano-emulsie inovatoare care potenţează efectul antiiflamator al ciclosporinei3,4. Prin noua recomandare de la NICE, IKERVIS® oferă o opţiune nouă şi importantă pentru tratamentul pacienţilor din Anglia la care lacrimile artificiale nu au avut efect. Scottish Medicine’s Consortium (SMC) a decis anul acesta în octombrie ca IKERVIS® sa fie disponibil şi pentru pacienţii din Scotia.5
As a specialty company dedicated to the ophthalmic field, Santen carries out research, development, sales, and marketing of pharmaceuticals. Santen is the market leader in Japan for prescription ophthalmic pharmaceuticals and sells products in over 50 countries. As a leading company in the field of ophthalmology, Santen aims to contribute to society by supplying valuable products and services to satisfy unmet medical needs. For more details, please see Santen’s website (www.santen.com).
Information provided in this press release contains forward-looking statements. The achievement of these forecasts is subject to risk and uncertainty from various sources. Therefore, please note that the actual results may differ significantly from the forecasts. Business performance and financial conditions are subject to the effects of changes in regulations made by the governments of Japan and other nations concerning medical insurance, drug pricing and other systems, and to fluctuations in market variables such as interest rates and foreign exchange rates. This press release is also prepared in other languages. However this English document is the original document, and documents prepared in other languages are for your reference only. In case of any discrepancy between the English and translated versions, the English version will prevail. Please refer to http://www.santen.eu for the original English document. 1 NICE advice, published at http://www.nice.org.uk/guidance/GID-TAG466/documents/final-appraisal-determination-document [accessed 4 November 2015]
2 Ikervis SmPC June 2015, available at https://www.medicines.org.uk/emc/medicine/305843 Lalleman F et al. J Drug Deliv 2012: 6042044 Daull P, et al. 2013 Mar; 32 (3): 345-545 SMC advice, published at https://www.scottishmedicines.org.uk/SMC_Advice/Advice_Directory/SMC_Advice_Directory [12 October 2015]http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002066/human_med_001851.jsp&mid=WC0b01ac058001d124